Want to see TSE:AVCN full AI Analyst Report?
AVCN Stock Chart & Stats
C$0.22
C$0.02(4.41%)
At close: 4:00 PM EST
C$0.22
C$0.02(4.41%)
Day’s Range― - ―
52-Week RangeC$0.11 - C$0.31
Previous CloseN/A
Volume8.50K
Average Volume (3M)55.79K
Market Cap
C$15.72M
Enterprise ValueC$16.30M
Total Cash (Recent Filing)C$372.10K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding125,791,870
10 Day Avg. Volume77,161
30 Day Avg. Volume55,794
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.08
Price to Sales (P/S)1.01
P/FCF Ratio-17.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Gross MarginsA material rise in gross margin to ~51% TTM indicates stronger product economics and pricing power in core formulations. Sustained higher gross margins improve operating leverage, reduce cash burn per dollar of revenue, and create a clearer path to profitability if SG&A growth is controlled over the medium term.
Debt-Free Balance SheetZero reported debt materially reduces refinancing and interest-rate risk for a capital-consuming biopharma. A debt-free structure preserves strategic optionality, limits fixed cash outflows, and gives management flexibility to prioritize R&D or commercial investments during a multi-quarter scaling phase without immediate repayment pressure.
Strong Revenue MomentumSharp TTM revenue growth signals improving market traction across pharmaceutical and consumer channels, validating product-market fit and distribution execution. Durable top-line expansion supports scale benefits and, combined with higher gross margins, increases the odds of converting revenue growth into sustainable earnings over several quarters.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow means the business does not self-fund its operations or investments. Over a multi-quarter horizon this raises the probability of external financing needs, which can dilute shareholders and constrain the company’s ability to sustain R&D, commercial expansion, or respond to market setbacks.
Ongoing Net LossesContinued operating losses and a roughly -14% net margin indicate the company has not converted revenue gains into profitability. Persistent losses weaken returns on equity and could erode balance sheet resilience if cash burn continues, limiting long-term strategic choices absent a clear path to break-even.
Elevated Funding & Execution RiskNegative profitability alongside meaningful cash burn elevates execution and funding risk: management may need to raise capital or curtail investments. Such outcomes can delay product commercialization, shift strategic priorities, or increase dilution, all of which can materially affect the company’s multi-quarter growth trajectory.
Avicanna News
AVCN FAQ
What was Avicanna’s price range in the past 12 months?
Avicanna lowest stock price was C$0.10 and its highest was C$0.31 in the past 12 months.
What is Avicanna’s market cap?
Avicanna’s market cap is C$15.72M.
When is Avicanna’s upcoming earnings report date?
Avicanna’s upcoming earnings report date is Aug 17, 2026 which is in 46 days.
How were Avicanna’s earnings last quarter?
Currently, no data Available
Is Avicanna overvalued?
According to Wall Street analysts Avicanna’s price is currently Overvalued.
Does Avicanna pay dividends?
Avicanna does not currently pay dividends.
What is Avicanna’s EPS estimate?
Avicanna’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avicanna have?
Avicanna has 125,791,870 shares outstanding.
What happened to Avicanna’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avicanna?
Currently, no hedge funds are holding shares in TSE:AVCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avicanna
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health markets. The company's comprehensive scientific framework encompasses R&D and clinical trials, often undertaken in collaboration with Canadian academic and medical institutions. This effort has yielded around twenty commercialized products spanning four primary market categories. These offerings include medical and wellness items under the RHO Phyto brand, featuring cannabinoids such as CBD, CBG, and THC; CBD-infused topical and derma-cosmetic products marketed under the Pura H&W and Pura Earth labels; and bulk cannabis and hemp-derived raw materials like dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, and isolates, provided through the Aureus brand. Additionally, Avicanna is advancing a pharmaceutical pipeline focused on treatments for conditions including epidermolysis bullosa, dermatological ailments, chronic pain, and various neurological disorders. A notable research partnership with Dr. Christine Allen's Research Group is dedicated to developing a cannabinoid-based therapy for lung inflammation linked to COVID-19.
Technical Analysis
Charlotte's Web Holdings
―
MediPharm Labs
―
PharmaCielo
―
Cardiol Therapeutics
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---